Oncolytics Biotech Inc
Stocks in Play Oncolytics Biotech Inc has announced positive results from its Phase 1/2 GOBLET study, which tested pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC). The study was presented at the European Society for Medical Oncology meeting (ESMO 2023) in Madrid, Spain. Highlights include a 25% increase in historical outcomes and T-cell expansion data indicating an important proof-of-concept for the treatment. Shares of T.ONC are currently unchanged at $2.14.
Được phát hành : 2 năm trước qua Baystreet Staff trong Tech
09:24 AM EST - Oncolytics Biotech Inc : Announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain. Highlights include; 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by = 25%; also
T-cell expansion data correlate with tumor response, providing important proof-of-concept. Oncolytics Biotech Inc shares T.ONC are trading unchanged at $2.14.
Chủ đề: Biotech